Brolucizumab
Brolucizumab
Brolucizumab (pronounced bro-loo-ci-zoo-mab) is a type of medication used in the treatment of neovascular (wet) age-related macular degeneration (nAMD). It is a humanized single-chain antibody fragment (scFv) and works by inhibiting vascular endothelial growth factor A (VEGF-A).
Etymology
The name Brolucizumab is derived from the scientific name of the molecule. The suffix "-mab" is used for monoclonal antibodies, indicating the drug's class. The prefix "bro-" is an arbitrary syllable, and "luciz-" is a stem used for substances related to the eye or vision.
Usage
Brolucizumab is administered via intravitreal injection into the affected eye. It is used to slow the progression of nAMD and to improve visual acuity. The drug works by inhibiting the action of VEGF-A, a protein that promotes the growth of new blood vessels. By blocking this protein, Brolucizumab can help to reduce the growth of abnormal blood vessels in the retina, a key factor in the progression of nAMD.
Related Terms
- Monoclonal Antibodies: A type of drug that is made to target and bind to specific proteins in the body. Brolucizumab is a type of monoclonal antibody.
- Neovascular Age-Related Macular Degeneration: A condition that affects the macula, the part of the eye that provides sharp, central vision. Brolucizumab is used to treat this condition.
- Vascular Endothelial Growth Factor A: A protein that promotes the growth of new blood vessels. Brolucizumab works by inhibiting this protein.
- Intravitreal Injection: A method of delivering medication directly into the eye. Brolucizumab is administered in this way.
External links
- Medical encyclopedia article on Brolucizumab
- Wikipedia's article - Brolucizumab
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski